Stallergenes Greer Overview
Pro stress-test →Stallergenes Greer is a leading global biopharmaceutical company specialising in allergen immunotherapy for human and veterinary use, with activities spanning the full value chain from product development and commercialisation to allergy diagnosis and treatment. Backed by more than 120 years of expertise and innovation, the company's products reach patients in 46 countries worldwide.
Strategic Profile
Pro stress-test →The company offers treatment of severe allergic rhinitis with allergen immunotherapy, including sublingual products, subcutaneous products, enzyme-linked immunosorbent assay components and prescription services. In June 2026, Stallergenes Greer announced a strategic investment of over €125 million by 2030 in its Antony site in France to expand and upgrade its industrial capacity.
Competitive Landscape
Pro stress-test →Stallergenes Greer competes in the allergen immunotherapy space against major pharmaceutical companies with allergy divisions. Key competitors include companies offering sublingual immunotherapy (SLIT), subcutaneous immunotherapy (SCIT), and oral immunotherapy (OIT) products. The company's integrated approach covering diagnostics, therapeutic development, manufacturing, and distribution provides a comprehensive competitive advantage in the specialty allergy treatment market.
Industry Context
Stallergenes Greer operates in Specialty Pharmaceuticals / Allergen Immunotherapy.
Key facts
Founded: 2015 · Headquarters: Baar, Switzerland · Employees: 1,200 · Revenue: $100M–$1B (estimated)